loading
Oramed Pharmaceuticals Inc stock is traded at $2.20, with a volume of 63,816. It is up +3.29% in the last 24 hours and up +5.26% over the past month.
See More
Previous Close:
$2.13
Open:
$2.11
24h Volume:
63,816
Relative Volume:
0.27
Market Cap:
$85.86M
Revenue:
$2.70M
Net Income/Loss:
$5.53M
P/E Ratio:
20.00
EPS:
0.11
Net Cash Flow:
$-10.55M
1W Performance:
-6.78%
1M Performance:
+5.26%
6M Performance:
-7.95%
1Y Performance:
-21.43%
1-Day Range:
Value
$2.11
$2.20
1-Week Range:
Value
$2.06
$2.404
52-Week Range:
Value
$1.9929
$3.09

Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile

Name
Name
Oramed Pharmaceuticals Inc
Name
Phone
646-844-1164
Name
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Name
Employee
0
Name
Twitter
@OramedPharma
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
ORMP's Discussions on Twitter

Compare ORMP with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ORMP
Oramed Pharmaceuticals Inc
2.20 85.86M 2.70M 5.53M -10.55M 0.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-12-23 Downgrade Canaccord Genuity Buy → Hold
Feb-18-22 Initiated Cantor Fitzgerald Overweight
Apr-20-21 Initiated Canaccord Genuity Buy
Feb-09-21 Initiated National Securities Buy
Dec-03-20 Initiated Alliance Global Partners Buy
Mar-11-20 Initiated Aegis Capital Buy
Sep-11-19 Initiated Ladenburg Thalmann Buy
Dec-11-17 Resumed B. Riley FBR, Inc. Buy
May-26-16 Reiterated FBR Capital Outperform
Dec-01-15 Reiterated H.C. Wainwright Buy
Nov-19-15 Initiated FBR Capital Outperform
Apr-13-15 Resumed MLV & Co Buy
Jan-30-14 Reiterated Aegis Capital Buy
Jan-08-14 Reiterated Aegis Capital Buy
Jan-08-14 Initiated MLV & Co Buy
Dec-03-13 Initiated Aegis Capital Buy
View All

Oramed Pharmaceuticals Inc Stock (ORMP) Latest News

pulisher
Mar 24, 2025

Oral Biologics Market Is Booming Worldwide 2025-2032 | Biocon - openPR.com

Mar 24, 2025
pulisher
Mar 21, 2025

Oramed Pharmaceuticals Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView

Mar 21, 2025
pulisher
Mar 13, 2025

Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential - Simply Wall St

Mar 13, 2025
pulisher
Mar 12, 2025

Oramed Pharmaceuticals Stock Plummets After Insulin Test Results - The Wall Street Journal

Mar 12, 2025
pulisher
Mar 10, 2025

Tianhui Biotech and Oramed Pharmaceuticals’ Investment in OraTech Pharmaceuticals - Global Legal Chronicle

Mar 10, 2025
pulisher
Mar 08, 2025

AllPennyStocks.com Releases a Special Report on Oramed Pharmaceuticals Inc. - ACCESS Newswire

Mar 08, 2025
pulisher
Mar 04, 2025

Oramed advances oral insulin, plans Phase 3 trial and dividend - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Oramed advances oral insulin, plans Phase 3 trial and dividend By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Oramed Pharmaceuticals Issues Letter to Shareholders - PR Newswire

Mar 04, 2025
pulisher
Mar 03, 2025

ORMP stock touches 52-week low at $2 amid market challenges By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 03, 2025

ORMP stock touches 52-week low at $2 amid market challenges - Investing.com

Mar 03, 2025
pulisher
Mar 01, 2025

Short Interest in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Expands By 149.0% - Armenian Reporter

Mar 01, 2025
pulisher
Feb 28, 2025

OraMed Enters Global Licensing Deal for Lidocaine Product By Investing.com - Investing.com Australia

Feb 28, 2025
pulisher
Feb 27, 2025

Oramed Pharmaceuticals (ORMP) to Release Quarterly Earnings on Wednesday - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

OraMed Enters Global Licensing Deal for Lidocaine Product - Investing.com India

Feb 27, 2025
pulisher
Feb 27, 2025

Rep. Brad Knott Sells Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares - MarketBeat

Feb 27, 2025
pulisher
Feb 26, 2025

Congressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals Stock - Benzinga

Feb 26, 2025
pulisher
Feb 22, 2025

Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded to Sell Rating by StockNews.com - MarketBeat

Feb 22, 2025
pulisher
Feb 17, 2025

227,239 Shares in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Acquired by Peapod Lane Capital LLC - MarketBeat

Feb 17, 2025
pulisher
Feb 15, 2025

Oramed announces spinoff of protein drug technology - MSN

Feb 15, 2025
pulisher
Feb 12, 2025

OraTech to pioneer oral insulin with $75 million investment - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

Oramed Pharmaceuticals : Ancillary Agreement Completion Protocol and Supplemental Agreement - Marketscreener.com

Feb 12, 2025
pulisher
Feb 11, 2025

Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch - Simply Wall St

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed Pharm Amends Joint Venture for OraTech Launch - TipRanks

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed (ORMP) Stock Skyrockets Amid JV Development Plans - Stocks Telegraph

Feb 11, 2025
pulisher
Feb 11, 2025

OraTech to pioneer oral insulin with $75 million investment By Investing.com - Investing.com South Africa

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed Pharmaceuticals Forms Joint Venture to Commercialize Oral Insulin; Shares Rise - Marketscreener.com

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed Pharmaceuticals to Spin Off Its Protein Oral Delivery Technology - Contract Pharma

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed stock soars on spinoff plans (ORMP:NASDAQ) - Seeking Alpha

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed Announces Joint Venture To Develop And Commercialize Oral Insulin -February 11, 2025 at 09:17 am EST - Marketscreener.com

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin - PR Newswire

Feb 11, 2025
pulisher
Feb 11, 2025

Charting the Course: Viking Therapeutics Inc’s VKTX Stock Prospects - The InvestChronicle

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Lowered by StockNews.com - MarketBeat

Feb 11, 2025
pulisher
Feb 10, 2025

Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Below 200 Day Moving AverageTime to Sell? - MarketBeat

Feb 10, 2025
pulisher
Feb 04, 2025

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat

Feb 04, 2025
pulisher
Jan 31, 2025

Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Cross Below Two Hundred Day Moving Average – Here’s Why - Defense World

Jan 31, 2025
pulisher
Jan 24, 2025

Oramed Pharmaceuticals Extends Maturity Date of Senior Secured Promissory Note in Recent Amendment - Defense World

Jan 24, 2025
pulisher
Jan 22, 2025

Oramed Pharmaceuticals extends loan maturity, acquires Scilex shares - Investing.com

Jan 22, 2025
pulisher
Jan 21, 2025

Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025 - The Manila Times

Jan 21, 2025
pulisher
Jan 21, 2025

Scilex Holding Company Announces Extension of the Maturity - GlobeNewswire

Jan 21, 2025
pulisher
Jan 18, 2025

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Significant Decrease in Short Interest - MarketBeat

Jan 18, 2025
pulisher
Jan 14, 2025

Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to “Hold” at StockNews.com - Defense World

Jan 14, 2025
pulisher
Jan 13, 2025

Oramed Pharmaceuticals (NASDAQ:ORMP) Raised to Hold at StockNews.com - MarketBeat

Jan 13, 2025

Oramed Pharmaceuticals Inc Stock (ORMP) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Cap:     |  Volume (24h):